• when accuracy means everything

    when accuracy means everything

  • complete panel of diagnostics

    complete panel of diagnostics

  • at the end of every test is a patient

    at the end of every test is a patient

  • early detection improves outcomes

    early detection improves outcomes

  • your laboratory next door

    your laboratory next door

The total solution in autoimmunity™

Immco Diagnostics develops and distributes autoimmune disease diagnostics and reagents to labs worldwide. We offer laboratory testing of autoimmune diseases for the US healthcare market. Our contract research organization supports clinical research trials for pharmaceutical and biotech clients. Immco assay development led to the first immunofluorescence assay for diagnosing celiac disease and the first Western blot assay for autoimmune hearing loss. Our new line of enhanced ELISA assays provides standardized calibration systems, an industry first. We are continually expanding our product offering. So come visit us often as we focus on our principal mission at Immco—providing the total solution in autoimmunity™.

Products

Products

Immco offers a wide selection of autoimmune diagnostics under our leading brands: ImmuGlo™,ImmuLisa™, and ImmuBlot™

Immunofluorescence microscopy is the cornerstone of autoimmune diagnostics at Immco. As a leader in developing IFA (indirect immunofluoresence assays), we offer a full range of IFA products for detecting autoimmune disease. ImmuGlo™ is supported with flexible configurations and high quality reagents that ensure reproducibility and ease of use.

Immco ELISAs (enzyme linked immunosorbent assays) feature highly accurate qualitative and quantitative antibody detection for proper diagnosis of autoimmune disorders. Introduction of our new ImmuLisa™ Enhanced assays features industry leading advantages:

  • Antigens are selected and presented in a highly purified form for the highest accuracy
  • Standardized component sets and methods provide greater reproducibility
  • Optimal detection systems yield enhanced sensitivity and specificity
  • Optimal design for performance on all major automated ELISA platforms
  • Choice of single or multiple point calibration for greater flexibility
  • Longer shelf life up to 18 months to support laboratory needs.

Immco's ImmuBlot™ uses Western blot assay methodology to provide highly sensitive, qualitative detection of autoantibodies in serum. ImmuBlot™ assays feature leading reliability and are primarily used to identify specific analytes or serve as confirmatory tests.

Lab Services

Lab Services

Immco Reference Lab Services, specializing in autoimmune diseases and immunopathology, provides laboratory testing with over 200 cutting edge diagnostics using direct and indirect immunofluorescence (IFA), enzyme linked immunosorbent assays (ELISA), Western blot detection methods and biopsy studies to support healthcare practitioners across a wide clinical spectrum. We provide histopathology and serology for oral diagnostics, autoimmunology and immunogenetics for common autoimmune diseases such as lupus, rheumatoid arthritis, celiac disease, polymyositis, systemic sclerosis, and thyroiditis, as well as the less prevalent autoimmune disorders. Our laboratory testing includes:

  • Connective tissue disorder diagnostics for systemic lupus erythematosus, scleroderma, rheumatoid arthritis, and vasculitis
  • Gastrointestinal disease diagnostics including celiac disease, inflammatory bowel disorders, pernicious anemia and autoimmune gastritis
  • Liver disease diagnostics such as autoimmune hepatitis and primary biliary cirrhosis
  • Vesiculo-bullous disorder diagnostics for pemphigus, pemphigoid, and epidermolysis bullosa acquisita
  • Endocrine disorder diagnostics including Type 1 diabetes, Graves' disease, Hashimoto's thyroiditis, Addison's disease and premature ovarian dysfunction
  • Neurological diagnostics for peripheral neuropathies, paraneoplastic syndromes, Guillain-Barré Syndrome, Miller Fisher Syndrome, neuropsychiatric lupus, and myasthenia gravis
  • Cardiovascular diagnostics for patients at risk for atherosclerosis, myocarditis, and cardiomyopathy.

Featured Product

Clinical Specialties

Immco is Proud to Announce FDA Approval of ImmuLisa Enhanced™ Cardiolipin Antibody ELISAs

Immco Diagnostics has obtained 510k clearance for the following in vitro diagnostic use (IVD) kits:
5118A ACA IgA ELISA
5118G ACA IgG ELISA
5118M ACA IgM ELISA
5118S ACA Screen ELISA
For more information on Immco’s ELISA’s products, click on: http://www.immco.com/products/immulisa-elisa.aspx 

.

News

IMMCO DIAGNOSTICS LAUNCHES NEW PATENTED TESTS FOR DIAGNOSIS OF CHRONIC RHINOSINUSITIS

BUFFALO, New York – June 17, 2013 -- Immco Diagnostics Inc. (Immco), has received New York State Department of Health (NYSDOH) approval of the new patented laboratory tests for diagnosis of fungal-mediated Chronic Rhinosinusitis (CRS). CRS is a common and often debilitating form of sinusitis marked by prolonged or recurring inflammation of the nose and paranasal sinus. Diagnosis and treatment can be challenging and many sufferers improperly self-diagnose with nasal allergies and ineffectively self-treat their symptoms. Proper treatment for non-allergic fungal-mediated CRS differs significantly from treatment for allergies or other chronic inflammation of the sinus.

Immco in partnership with the Mayo Clinic has developed next generation diagnostics tests for fungal-mediated CRS. Testing is performed at the Immco reference laboratory, located on the Buffalo Niagara Medical Campus. Specimens are collected throughout the United States by ENTs (ear, nose and throat specialists) and sent to Immco.

“This technology represents an important advance in the proper diagnosis of fungal-mediated CRS. We hope that innovative, simplified diagnostics lead to improved quality of life for CRS sufferers,” said Bill Maggio, President and CEO, of Immco Diagnostics. With better diagnostic options, patients properly diagnosed with fungal-mediated CRS may benefit from a course of anti-fungal therapy. Removal of the fungal antigens will often cause the immunological inflammatory response to subside.

About Immco Diagnostics:
Immco incorporates innovative medical devices, laboratory testing expertise and pioneering research into comprehensive solutions for autoimmune disease diagnosis. Immco develops and distributes autoimmune disease test kits and reagents to labs worldwide. The company offers reference laboratory testing to the US healthcare market and well as contract research services supporting clinical trials for pharmaceutical and biotech clients.


Source: Immco Diagnostics, Inc.

William J. Maggio, CEO
Tel. +176 691 0091